Australian company Immutep (ASX:IMM) has reported positive results from a clinical trial of its LAG-3 immunotherapy in combination with MSD's PBS-listed anti-PD-1 therapy KEYTRUDA (pembrolizumab). …
Positive results for Australian company's cancer candidate in combination with MSD's Keytruda
May 18, 2023 Latest NewsBioPharmaAustralian Biotech
Latest Video
New Stories
-
The 'Week in Review' Podcast - 26 July
July 26, 2024 - - Podcast -
'We approached stakeholders that were highly engaged with the HTA review process'
July 26, 2024 - - Latest News -
Preaching transparency and not practising it is the worst possible look
July 26, 2024 - - Latest News -
Cartherics announces new licensing agreement for innovative cardiac cell therapy
July 25, 2024 - - Latest News -
New large study shows vaccination halves the risk of patients suffering Long-COVID
July 25, 2024 - - Latest News -
These layered levels of privilege are not making decision-making or the system better
July 25, 2024 - - Latest News -
Telix completes significant raise that could be used for acquisitions
July 25, 2024 - - Latest News